Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018

Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018


  • Products Id :- GDHC5086CTIDB
  • |
  • Pages: 167
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018

 

Summary

 

GlobalData's clinical trial report, Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H1, 2018" provides an overview of Relapsing Multiple Sclerosis (RMS) clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsing Multiple Sclerosis (RMS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database-Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

 

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

- The report provides a snapshot of the global clinical trials landscape

- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

- The Report provides enrollment trends for the past five years

- Report provides latest news for the past three months

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Reasons to buy

 

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost

- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

- Supports understanding of trials count and enrollment trends by country in global therapeutics market

- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

- Facilitates clinical trial assessment of the indication on a global, regional and country level

 

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials 16

Clinical Trials by Phase in G7 Countries 17

Clinical Trials in G7 Countries by Trial Status 18

Clinical Trials by E7 Countries: Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials 19

Clinical Trials by Phase in E7 Countries 20

Clinical Trials in E7 Countries by Trial Status 21

Clinical Trials by Phase 22

In Progress Trials by Phase 23

Clinical Trials by Trial Status 24

Clinical Trials by End Point Status 25

Subjects Recruited Over a Period of Time 26

Clinical Trials by Sponsor Type 27

Prominent Sponsors 28

Top Companies Participating in Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials 29

Prominent Drugs 30

Latest Clinical Trials News on Relapsing Multiple Sclerosis (RMS) 31

Jun 18, 2018: TG Therapeutics Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology 31

Jun 14, 2018: Roche announces new OCREVUS ocrelizumab data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis 31

Jun 06, 2018: Alkermes Receives USD 50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program 32

May 29, 2018: EMD Serono to Present MS Data and Debut New Patient Resources at CMSC 2018 32

May 02, 2018: Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients with Highly Active Multiple Sclerosis 34

Apr 27, 2018: Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL 34

Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting 34

Apr 23, 2018: New OCREVUS (ocrelizumab) data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis 35

Apr 23, 2018: Relapsing MS Patients Who Switched to Aubagio (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies 36

Apr 19, 2018: Sanofi Genzyme's Multiple Sclerosis Data to Be Featured at AAN 37

Apr 19, 2018: Sanofi Genzyme Presents Investigational Data on Aubagio(teriflunomide) at AAN 37

Apr 17, 2018: Teva to Present New Data on COPAXONE at 70th Annual Meeting of the American Academy of Neurology 38

Apr 15, 2018: Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus 38

Clinical Trial Profile Snapshots 40

Appendix 165

Abbreviations 165

Definitions 165

Research Methodology 166

Secondary Research 166

About GlobalData 167

Contact Us 167

Source 167

List of Figures

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15

Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16

Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 19

Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Relapsing Multiple Sclerosis (RMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

GlobalData Methodology 166

List of Tables

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Region, 2018* 8

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15

Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, G7 Countries (%), 2018* 16

Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17

Relapsing Multiple Sclerosis (RMS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18

Proportion of Relapsing Multiple Sclerosis (RMS) to Central Nervous System Clinical Trials, E7 Countries (%), 2018* 19

Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20

Relapsing Multiple Sclerosis (RMS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Phase, 2018* 22

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23

Relapsing Multiple Sclerosis (RMS) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26

Relapsing Multiple Sclerosis (RMS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29

Relapsing Multiple Sclerosis (RMS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Biogen Inc

Sanofi

E. Merck KG

Novartis AG

F. Hoffmann-La Roche Ltd

Teva Pharmaceutical Industries Ltd

Celgene Corp

Pharmaceutical Product Development LLC

Perrigo Company Plc

Johnson & Johnson

Relapsing Multiple Sclerosis (RMS) Clinical Trials, Phase, Completed, Ongoing, Planned, End Points, Trial Locations, Trial Designs, Subjects Recruited, Safety, Efficacy, Bioequivalence, Pharmacokinetics, Pharmacodynamic, Sponsor, Collaborator, CRO's, Terminated, Suspended and Withdrawn trials of Relapsing Multiple Sclerosis (RMS), Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas M. D. Anderson Cancer Center, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, University of Pennsylvania

select a license
Single User License
USD 2500 INR 178475
Site License
USD 5000 INR 356950
Corporate User License
USD 7500 INR 535425

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com